Ranolazine in Cardiac Arrhythmia.

Article Details

Citation

Copy to clipboard

Saad M, Mahmoud A, Elgendy IY, Richard Conti C

Ranolazine in Cardiac Arrhythmia.

Clin Cardiol. 2016 Mar;39(3):170-8. doi: 10.1002/clc.22476. Epub 2015 Oct 13.

PubMed ID

26459200 [ View in PubMed

]

Abstract

Ranolazine utilization in the management of refractory angina has been established by multiple randomized clinical studies. However, there is growing evidence showing an evolving role in the field of cardiac arrhythmias. Multiple experimental and clinical studies have evaluated the role of ranolazine in prevention and management of atrial fibrillation, with ongoing studies on its role in ventricular arrhythmias. In this review, we will discuss the pharmacological, experimental, and clinical evidence behind ranolazine use in the management of various cardiac arrhythmias.

DrugBank Data that Cites this Article

Drugs

Ranolazine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ranolazine	Inward rectifier potassium channel (Protein Group)	Protein group	Humans	Unknown	Inhibitor	Details
Ranolazine	Sodium channel protein (Protein Group)	Protein group	Humans	Unknown	Inhibitor	Details
Ranolazine	Voltage gated L-type calcium channel (Protein Group)	Protein group	Humans	Unknown	Inhibitor	Details

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Ranolazine	P-glycoprotein 1	Protein	Humans	No	Substrate Inhibitor	Details